Abstract:An oligodeoxynucleotide coding for amino acids 139 through 149 of antigenic site A (ASA) of the VP1 capsid protein of the foot-and-mouth disease virus C3 serotype (FMDV C3) was inserted into three different in-frame sites of the vesicular stomatitis virus New Jersey serotype (VSV-NJ) glycoprotein (G) gene cDNA present in plasmid pKG97 under control of the bacteriophage T7 polymerase promoter. Transfection of these plasmids into CV1 cells coinfected with the T7 polymerase-expressing vaccinia virus recombinant vTF1-6,2 resulted in expression of chimeric proteins efficiently reactive with both anti-FMDV and anti-VSV G antibodies. However, in vitro translation of transcripts of these VSV-G/FMDV-ASA chimeric plasmids resulted in proteins that were recognized by anti-G serum but not by anti-FMDV serum, indicating a requirement for in vivo conformation to expose the ASA antigenic determinant. Insertion of DNA coding for a dimer of the ASA unidecapeptide between the VSV-NJ G gene region coding for amino acids 160 and 161 gave rise to a chimeric ASA-dimer protein designated GF2d, which reacted twice as strongly with anti-FMDV antibody as did chimeric proteins in which the ASA monomer was inserted in the same position or two other G-gene positions. For even greater expression of chimeric VSV-G/FMDV-ASA proteins, plasmid pGF2d and a deletion mutant p(delta)GF2d (G protein deleted of 324 C-terminal amino acids) were inserted into baculovirus vectors expressing chimeric proteins GF2d-bac and deltaGF2d-bac produced in Sf9 insect cells. Mice vaccinated with three booster injections of 30 microg each of partially purified GF2d-bac protein responded by enzyme-linked immunosorbent assay with FMDV antibody titers of 1,000 units, and those injected with equivalent amounts of deltaGF2d-bac protein showed serum titers of up to 10,000 units. Particularly impressive were FMDV neutralizing antibody titers in serum of mice vaccinated with deltaGF2d-bac protein, which approached those in the sera of mice vaccinated with three 1-microg doses of native FMDV virions. Despite excellent reactivity with native FMDV, the anti-deltaGF2d-bac antibody present in vaccinated mouse serum showed no capacity to bind to sodium dodecyl sulfate (SDS)-denatured FMDV virions and only minimal reactivity with VP1 protein by Western blotting (immunoblotting) after SDS-polyacrylamide gel electrophoresis. It was also shown in a competitive binding assay that a synthetic ASA unidecapeptide, up to concentrations of 200 microg/ml, was quite limited in its ability to inhibit binding of anti-deltaGF2-bac antibody to native FMDV virions. These results suggest that the chimeric VSV-G/FMDV-ASA proteins mimic the capacity of FMDV to raise and react with neutralizing antibodies to a restricted number of ASA conformations present on the surface of native FMDV particles.

Functional Enhancement of a Partially Active Single-Chain Variable Fragment Antibody to Venezuelan Equine Encephalitis Virus.

Genetic Engineering of Streptavidin-Binding Peptide Tagged Single-Chain Variable Fragment Antibody to Venezuelan Equine Encephalitis Virus

Development and Characterization of a Novel Fusion Protein Composed of a Human IgG1 Heavy Chain Constant Region and a Single-Chain Fragment Variable Antibody Against Venezuelan Equine Encephalitis Virus.

Combining computational modeling and experimental library screening to affinity-mature VEEV-neutralizing antibody F5

A Recombinant Humanized Monoclonal Antibody Completely Protects Mice Against Lethal Challenge with Venezuelan Equine Encephalitis Virus.

Therapeutic efficacy of a potent anti-Venezuelan equine encephalitis virus antibody is contingent on Fc effector function

Humanization and mammalian expression of a murine monoclonal antibody against Venezuelan equine encephalitis virus.

Requirement for Fc effector function is overcome by binding potency for broadly reactive anti-alphavirus antibodies

Development of Immunofiltration Assay by Light Addressable Potentiometric Sensor with Genetically Biotinylated Recombinant Antibody for Rapid Identification of Venezuelan Equine Encephalitis Virus

Cross-Strain Neutralizing and Protective Monoclonal Antibodies against EEEV or WEEV

Construction and Expression of Single-Chain Antibody Derived from a New Clone of Monoclonal Antibody Against Human CD14 in CHO Cells

[Construction and Expression of Prokaryotic Vector of Single Chain Antibody Derived from a New Clone of Anti-Cd14 Antibody ZCH-7-2F9].

Preparation and identification of a single-chain variable fragment antibody against Newcastle diseases virus F48E9.

Selection and characterization of single-chain recombinant antibodies against phosphoprotein of Newcastle disease virus.

Amino Acid Mutations of the Infectious Clone from Chinese EIAV Attenuated Vaccine Resulted in Reversion of Virulence.

Cloning, expression and purification of envelope proteins E1 and E2 of western equine encephalitis virus and potential use of them as antigens in immunoassays

Approach to Strain Selection and the Propagation of Viral Stocks for Venezuelan Equine Encephalitis Virus Vaccine Efficacy Testing under the Animal Rule

Generation and characterisation of recombinant FMDV antibodies: Applications for advancing diagnostic and laboratory assays

A broadly reactive ultralong bovine antibody that can determine the integrity of foot-and-mouth disease virus capsids

Mapping of foot-and-mouth disease virus antigenic sites recognized by single-domain antibodies reveals different 146S particle specific sites and particle flexibility

Immunogenicity of an aphthovirus chimera of the glycoprotein of vesicular stomatitis virus